• Aucun résultat trouvé

From tumorigenesis to cell death: the aneuploidy paradox

N/A
N/A
Protected

Academic year: 2021

Partager "From tumorigenesis to cell death: the aneuploidy paradox"

Copied!
11
0
0

Texte intégral

(1)

HAL Id: hal-02495035

https://hal.archives-ouvertes.fr/hal-02495035

Submitted on 28 Aug 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of sci-entific research documents, whether they are pub-lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

From tumorigenesis to cell death: the aneuploidy

paradox

Clara Nahmias, Sylvie Rodrigues-Ferreira

To cite this version:

Clara Nahmias, Sylvie Rodrigues-Ferreira. From tumorigenesis to cell death: the aneu-ploidy paradox. Molecular & Cellular Oncology, Taylor et Francis, 2020, 7 (2), pp.1709390. �10.1080/23723556.2019.1709390�. �hal-02495035�

(2)

Molecular & Cellular Oncology

From tumorigenesis to cell death: the aneuploidy paradox

--Manuscript

Draft--Full Title: From tumorigenesis to cell death: the aneuploidy paradox Manuscript Number: 2019-KMCO-0102R1

Article Type: Author's Views

Keywords: Breast cancer; ATIP3; predictive biomarker; multipolar spindle; chromosome instability

Abstract: Aneuploidy, an abnormal chromosome number, is a hallmark of cancer. We recently showed that depletion of microtubule-associated protein ATIP3 (AT2

receptor-interacting protein 3) induces aneuploidy and sensitizes breast cancer cells to taxanes. Combining taxane treatment with ATIP3 depletion cooperates to reach a detrimental level of aneuploidy.

Order of Authors: Sylvie Rodrigues-Ferreira, Ph.D. Clara Nahmias, Ph.D.

Response to Reviewers: Thank you for your careful examination of our manuscript. We have now modified our manuscript accordingly.

We now explain the abbreviations when necessary, we have removed reference #11 to keep only 10 references, we are now referring to Figure 1 in the text and we have modified the title of figure 1.

You will find a revised version according to these comments.

We hope that our revised manuscript will now be suitable for publication in Molecular and Cellular Oncology.

With best regards, Clara Nahmias

(3)

From tumorigenesis to cell death: the aneuploidy paradox

Sylvie Rodrigues-Ferreira1,2,3,4& Clara Nahmias1,2,3*

1. Inserm U981, Department of Molecular Medicine, Gustave Roussy Cancer center, 94800 Villejuif, France.

2. LabEx LERMIT, University Paris Saclay, 92296 Châtenay-Malabry, France. 3. University Paris Sud, 94270 Le Kremlin-Bicetre, France.

4. Inovarion SAS, 75005 Paris, France.

*Correspondence:

Clara Nahmias, PhD., Inserm U981, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94800 Villejuif. Email: clara.nahmias@inserm.frTel : (+33) 682 00 69 33

Manuscript 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

(4)

2

Abstract

Aneuploidy, an abnormal chromosome number, is a hallmark of cancer. We recently showed that depletion of microtubule-associated protein ATIP3 (AT2 receptor-interacting protein 3) induces aneuploidy and sensitizes breast cancer cells to taxanes. Combining taxane treatment with ATIP3 depletion cooperates to reach a detrimental level of aneuploidy.

Key words (5-10)

Breast cancer, MTUS1, ATIP3, predictive biomarker, taxanes, multipolar spindle, centrosome amplification, chromosome instability.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65

(5)

Aneuploidy, an abnormal chromosome number, is a hallmark of cancer. Aneuploidy can arise by several mechanism but frequently occurs as a result of aberrant mitotic division. In particular, checkpoint signaling defects, improper attachment of chromosomes to spindle microtubules, or multipolar division frequently give rise to aneuploid cells.1 The consequence of aneuploidy is still a matter of debate. In cancer

cells, while aneuploidy is associated with tumorigenesis and poor prognosis, it has also been shown to reduce tumor growth and to promote cell death.2 Several studies aimed

at understanding this paradox and led to the notion of threshold. Thus, considering the rate of chromosome missegregation and aneuploidy, it was demonstrated that induction of aneuploidy confers cancer cell advantages and promotes tumorigenesis, while excessive aneuploidy is deleterious and leads to cell death and tumor suppression.3

Of interest, aneuploidy and chromosomal instability (CIN), a high frequency of genomic alterations, are induced by cytotoxic drugs used in chemotherapy. In breast cancer, chemotherapy regimen includes DNA targeting agents (anthracyclines) and microtubule poisons (taxanes). By inducing either DNA damage or multipolar spindles, these drugs impair chromosome segregation and promote cell death.4 However, this

treatment only benefits to 10-20% of breast cancer patients. The identification of biomarkers able to predict sensitivity to chemotherapy is an important issue to select patients who may benefit from chemotherapy and thus to avoid unnecessary treatment and side effects for those who remain resistant. Whether aneuploidy may be considered as a predictive biomarker for tumor response to chemotherapy is under investigation.

In a recent study comparing transcriptional and clinical data from three independent cohorts of breast cancer patients treated in neoadjuvant setting with taxane-based chemotherapy, we identified the microtubule-associated protein ATIP3 (AT2 receptor-interacting protein 3) as a new predictive biomarker of tumor response to chemotherapy. We showed (Figure 1) that low level of ATIP3 in breast tumors is associated with higher sensitivity to chemotherapy and can predict response to treatment with a good accuracy.5 ATIP3 is encoded by microtubule-associated tumor

suppressor gene (known as MTUS1). Our previous studies have shown that ATIP3 is significantly down-regulated in 47% of invasive breast carcinomas and 85% of triple-negative breast tumors.6 ATIP3 represents a prognostic biomarker of breast cancer

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

(6)

4 patients’ survival.7 At the molecular level, ATIP3 closely associates with the

microtubule cytoskeleton in interphase and with the mitotic spindle during mitosis.6

ATIP3 is a potent microtubule-stabilizing protein, its depletion being associated with increased microtubule dynamic instability that accounts for increasing breast cancer cell growth, polarity and migration.6,7

In our recent study,5 we showed that loss of ATIP3 not only predicts the response to

taxane-based chemotherapy but also enhances sensitivity to treatment in breast patient’s-derived xenografts and in multicellular spheroids models. Interestingly, depletion of ATIP3 increases cell death upon taxane treatment without affecting sensitivity to anthracyclines. As taxanes stabilize the microtubule network and impair cell division, we performed immunofluorescence and time-lapse experiments to evaluate the consequences of ATIP3 depletion on cell division upon taxane treatment. Our studies demonstrated that silencing of ATIP3 induces mitotic defects including centrosomes amplification and multipolar spindles. These defects are associated with chromosomes missegregation and increased aneuploidy, as measured by chromosome number after metaphase chromosome spreading. After treatment with low doses of taxanes, all mitotic abnormalities induced by ATIP3 silencing were exacerbated, further increasing the percentage of aneuploid cells and cell death. Thus, combining ATIP3 silencing with taxane treatment led to high rate of multipolar spindles, over amplification of centrosomes, increased aneuploidy and cell death, indicating that taxane treatment cooperates with ATIP3 depletion to reach a detrimental level of chromosomal instability (Figure 1). In line with these results, several studies have demonstrated that increasing aneuploidy in breast cancer cells either by inducing DNA damage, or altering mitotic regulators or centrosome numbers, potentiates the anti-tumoral effect of taxanes.8-10

Interestingly, using a breast cancer patient’s cohort in which aneuploidy has been evaluated, we found that 65% of low-ATIP3 expressing breast tumors are aneuploid as compared to 42% of high-ATIP3 tumors. The genomic alterations were also evaluated in breast tumors using a 25-genes signature of chromosomal instability (CIN). Our study showed that 60% of low-ATIP3 tumors are associated with high CIN compared to 40% of high-ATIP3 counterparts.5 Taken together, these results support

the notion that the frequency of aneuploidy in a tumor may determine the response to taxane-based chemotherapy, aneuploid tumors being more chemosensitive than

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65

(7)

diploid tumors. This point is under investigation in a clinical study that evaluates whether breast cancers with high chromosomal instability (CIN) may respond better to taxane-based chemotherapy than low-CIN cancers (NCT03096418).

Strategies to target aneuploidy in breast tumors may represent an interesting therapeutic option to improve sensitivity to taxane-based chemotherapy. As aneuploidy is very rare in normal cells, compounds able to impair chromosome segregation and to increase aneuploidy may show high specificity to cancer cells and few side effects.

Acknowledgements

This work has been funded by Gustave Roussy, CNRS, INSERM, the Comité Ile-de-France of the Ligue Nationale contre le Cancer, the Ligue contre le Cancer 94/Val-de-Marne, the Fondation ARC, the Fondation Janssen Horizon, the Fonds de Dotation Agnès b., the association Odyssea and Prolific.

Disclosure of potential conflict of interest

The authors report no conflict of interest

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

(8)

6

References

1-Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nat Rev Genet. 2012;13(3):189-203. doi: 10.1038/nrg3123. Review.

2-Santaguida S, Amon A. Short- and long-term effects of chromosome mis-segregation and aneuploidy. Nat Rev Mol Cell Biol. 2015;16(8):473-85. doi:

10.1038/nrm4025.

3-Silk AD, Zasadil LM, Holland AJ, Vitre B, Cleveland DW, Weaver BA. Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors Proc Natl Acad Sci U S A. 2013;110(44):E4134-41. doi: 10.1073/pnas.1317042110.

4-Zasadil LM, Andersen KA, Yeum D, Rocque GB, Wilke LG, Tevaarwerk AJ, Raines RT, Burkard ME, Weaver BA. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med.

2014;6(229):229ra43. doi:10.1126/scitranslmed.3007965.

5-Rodrigues-Ferreira S, Nehlig A, Moindjie H, Monchecourt C, Seiler C, Marangoni E, Chateau-Joubert S, Dujaric ME, Servant N, Asselain B, et al. Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy. Proc Natl Acad Sci U S A.

2019;16(47):23691-23697. doi: 10.1073/pnas.1910824116.

6-Rodrigues-Ferreira S, Di Tommaso A, Dimitrov A, Cazaubon S, Gruel N, Colasson H, Nicolas A, Chaverot N, Molinié V, Reyal F, et al. 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis.PLoS One. 2009;4(10):e7239. doi:10.1371/journal.pone.0007239.

7-Molina A, Velot L, Ghouinem L, Abdelkarim M, Bouchet BP, Luissint AC, Bouhlel I, Morel M, Sapharikas E, Di Tommaso A, et al. ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics. Cancer Res. 2013;73(9):2905-15. doi: 10.1158/0008-5472. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65

(9)

8-Wilhelm T, Olziersky AM, Harry D, De Sousa F, Vassal H, Eskat A, Meraldi P. Mild replication stress causes chromosome mis-segregation via premature centriole disengagement. Nat Commun. 2019;10(1):3585. doi: 10.1038/s41467-019-11584-0.

9-Cánovas B, Igea A, Sartori AA, Gomis RR, Paull TT, Isoda M, Pérez-Montoyo H, Serra V, González-Suárez E, Stracker TH, Nebreda AR. Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells. Cancer Cell. 2018;33(6):1094-1110.e8. doi:

10.1016/j.ccell.2018.04.010.

10-Maia ARR, Linder S, Song JY, Vaarting C, Boon U, Pritchard CEJ, Velds A, Huijbers IJ, van Tellingen O, Jonkers J, Medema RH. Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division. Br J Cancer. 2018;118(12):1586-1595. doi: 10.1038/s41416-018-0081-2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

(10)

8

Legend to Figure 1.

Effects of taxanes on breast cancers expressing or not ATIP3.

At the tumor level, only 1% of patients with AT2 receptor-interacting protein 3 (ATIP3)-positive tumors achieve pathological Complete Response (pCR) - a marker of chemosensitivity - upon taxane-based chemotherapy, compared to 30-40% of ATIP3-negative tumors.

In ATIP3-postive cells, taxanes induce mitotic defects such as multipolar spindles (MPS) that lead to aneuploidy. Silencing of ATIP3 also induces multipolar spindles and aneuploidy, a phenotype strongly exacerbated by taxane treatment.

Taxane treatment of positive tumors gives rise to abnormal mitosis. In ATIP3-negative tumors, that are aneuploid, taxane treatment further increases aneuploidy over a threshold (red dashed line) which is deleterious and promotes cell death.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65

(11)

Tu

mor

Cell

ATIP3-positive

ATIP3-negative

taxanes

taxanes

30-40% pCR

1% pCR

taxanes

taxanes

20 % MPS

4 % MPS

80 % MPS

0 % MPS

Cell death

taxanes

Abnormal mitosis

th re sh o ld

taxanes

th re sh o ld

r

ou

tc

ome

Graphical abstract

Références

Documents relatifs

By cross-omics analysis we demonstrate that although the deregulated miRNAs differ among individual aneuploid cell lines, their known targets are predominantly associated with

As we provide molecularly oriented de fi nitions of terms including intrinsic apoptosis, extrinsic apoptosis, mitochondrial permeability transition (MPT)-driven necrosis,

In this review, we discuss our current understanding of the molecular machinery of each of the main types of non-apoptotic RCD, including necroptosis, pyroptosis, ferroptosis,

At least theoretically, the co-administration of ER stressors or molecules that promote EIF2A phosphorylation can be harnessed to reconstitute the immunogenicity of RCD induced by

The treatment consists in the intravenous injection of cetuximab saratolacan, which binds to head and neck cancer cells expressing high levels of EGFR, followed by illumination of

Fatty acid synthase (FASN) is overexpressed in MM patients and the inhibition of β -oxidation as well as de novo fatty acid synthesis induces MM cell death including BTZ-resistant

The 2-D graph (Figure 3) reveals a striking separation of the stable states into 4 clusters: one cluster (blue circles) devoid of significant activity, which we call the ‘naı¨ve’

the high anti-proliferative activity of MC2884 in both leukemic models: in NB4 cells human CD45 + cells reduced to 17%, while in U937 to 24% in the bone marrow (Figure 4A,